Inhibitor Therapeutics Stock Analysis
| INTI Stock | USD 0.04 0.00 0.00% |
Inhibitor Therapeutics is overvalued with Real Value of 0.041 and Hype Value of 0.05. The main objective of Inhibitor Therapeutics otc analysis is to determine its intrinsic value, which is an estimate of what Inhibitor Therapeutics is worth, separate from its market price. There are two main types of Inhibitor Therapeutics' stock analysis: fundamental analysis and technical analysis.
The Inhibitor Therapeutics otc stock is traded in the USA on OTCQB Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Here, you can get updates on important government artifacts, including earning estimates, SEC corporate filings, announcements, and Inhibitor Therapeutics' ongoing operational relationships across important fundamental and technical indicators.
Inhibitor |
Inhibitor OTC Stock Analysis Notes
About 79.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.0. Inhibitor Therapeutics had not issued any dividends in recent years. Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.The quote for Inhibitor Therapeutics is listed on Over The Counter exchange (i.e., OTC), and the entity is not required to meet listing requirements such as those found on the Nasdaq, NYSE, or AMEX exchanges. To learn more about Inhibitor Therapeutics call Nicholas Virca at 888 841 6811 or check out https://www.inhibitortx.com.Inhibitor Therapeutics Investment Alerts
| Inhibitor Therapeutics had very high historical volatility over the last 90 days | |
| Inhibitor Therapeutics has some characteristics of a very speculative penny stock | |
| Inhibitor Therapeutics currently holds 331 K in liabilities with Debt to Equity (D/E) ratio of 11.81, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Inhibitor Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Inhibitor Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Inhibitor Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Inhibitor Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Inhibitor to invest in growth at high rates of return. When we think about Inhibitor Therapeutics' use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (298.63 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Inhibitor Therapeutics currently holds about 24.95 K in cash with (220.43 K) of positive cash flow from operations. | |
| Roughly 79.0% of Inhibitor Therapeutics shares are held by company insiders |
Inhibitor Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 22.99 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Inhibitor Therapeutics's market, we take the total number of its shares issued and multiply it by Inhibitor Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.Technical Drivers
As of the 30th of December, Inhibitor Therapeutics retains the Market Risk Adjusted Performance of (0.22), downside deviation of 11.88, and Risk Adjusted Performance of 0.0276. Inhibitor Therapeutics technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices. Simply put, you can use this information to find out if the firm will indeed mirror its model of historical price patterns, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Inhibitor Therapeutics, which can be compared to its competitors.Inhibitor Therapeutics Price Movement Analysis
The output start index for this execution was one with a total number of output elements of sixty. The Parabolic SAR indicator is used to determine the direction of Inhibitor Therapeutics's momentum and the point in time when Inhibitor Therapeutics has higher than normal probability directional change.
Inhibitor Therapeutics Outstanding Bonds
Inhibitor Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Inhibitor Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Inhibitor bonds can be classified according to their maturity, which is the date when Inhibitor Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View |
Inhibitor Therapeutics Predictive Daily Indicators
Inhibitor Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Inhibitor Therapeutics otc stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Inhibitor Therapeutics Forecast Models
Inhibitor Therapeutics' time-series forecasting models are one of many Inhibitor Therapeutics' otc stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Inhibitor Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.About Inhibitor OTC Stock Analysis
OTC Stock analysis is the technique used by a trader or investor to examine and evaluate how Inhibitor Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Inhibitor shares will generate the highest return on investment. We also built our otc analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual OTC such as Inhibitor Therapeutics. By using and applying Inhibitor OTC Stock analysis, traders can create a robust methodology for identifying Inhibitor entry and exit points for their positions.
Inhibitor Therapeutics, Inc., a pharmaceutical development company, develops and commercializes therapeutics for patients with certain cancers and non-cancerous proliferation disorders in the United States. Inhibitor Therapeutics, Inc. was founded in 1992 and is based in Tampa, Florida. Inhibitor Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our otc stock analysis tools, you can find out how much better you can do when adding Inhibitor Therapeutics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Watchlist Optimization Now
Watchlist OptimizationOptimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |
| All Next | Launch Module |
Complementary Tools for Inhibitor OTC Stock analysis
When running Inhibitor Therapeutics' price analysis, check to measure Inhibitor Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibitor Therapeutics is operating at the current time. Most of Inhibitor Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibitor Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibitor Therapeutics' price. Additionally, you may evaluate how the addition of Inhibitor Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |